SOHM Achieves Breakthrough with ABBIE Gene Editing Platform, Advancing Strategic Partnership and Licensing Opportunities
SOHM (OTC:SHMN) has achieved a significant breakthrough in gene editing technology with its proprietary ABBIE platform version 2. The company successfully demonstrated that its advanced dCas12a domain can effectively modify human cells, enabling multi-target editing capabilities through crRNA arrays.
The company has also successfully cloned an ovarian cancer cell line with confirmed GYS1 enzyme overexpression, demonstrating immediate commercial applications in drug screening, research partnerships, and diagnostic development. This positions SOHM for strategic partnerships and licensing opportunities in the rapidly growing genome editing market, projected to reach $25 billion by 2030 with a CAGR of 16.1%.
SOHM (OTC:SHMN) ha raggiunto una svolta importante nella tecnologia di editing genico con la sua piattaforma proprietaria ABBIE versione 2. L'azienda ha dimostrato con successo che il suo avanzato dominio dCas12a pu貌 modificare efficacemente cellule umane, permettendo modifiche multiple bersaglio tramite array di crRNA.
Inoltre ha clonato con successo una linea cellulare di carcinoma ovarico con sovraespressione confermata dell'enzima GYS1, evidenziando immediati sbocchi commerciali in screening farmacologici, collaborazioni di ricerca e sviluppo diagnostico. Ci貌 posiziona SOHM per partnership strategiche e opportunit脿 di licenza in un mercato dell'editing genomico in rapida crescita, stimato raggiungere $25 billion by 2030 con un CAGR del 16,1%.
SOHM (OTC:SHMN) ha logrado un avance importante en la tecnolog铆a de edici贸n gen茅tica con su plataforma propietaria ABBIE versi贸n 2. La compa帽铆a demostr贸 con 茅xito que su avanzado dominio dCas12a puede modificar c茅lulas humanas de forma efectiva, permitiendo edici贸n multi-objetivo mediante arreglos de crRNA.
Tambi茅n ha clonado con 茅xito una l铆nea celular de c谩ncer de ovario con sobreexpresi贸n confirmada de la enzima GYS1, mostrando aplicaciones comerciales inmediatas en cribado de f谩rmacos, colaboraciones de investigaci贸n y desarrollo de diagn贸sticos. Esto posiciona a SOHM para asociaciones estrat茅gicas y oportunidades de licencia en el mercado de edici贸n gen贸mica, que se espera alcance $25 billion by 2030 con una tasa compuesta anual del 16,1%.
SOHM (OTC:SHMN)電� 鞛愳泊 臧滊皽頃� ABBIE 頂岆灚韽� 氩勳爠 2搿� 鞙犾爠鞛� 韼胳 旮办垹鞐� 鞛堨柎 欷戩殧頃� 霃岉寣甑ゼ 鞚措鞀惦媹雼�. 須岇偓電� 歆勲炒霅� dCas12a 霃勲⿺鞚胳澊 鞚胳泊 靹疙彫毳� 須臣鞝侅溂搿� 氤�順曧暊 靾� 鞛堨潓鞚� 鞛呾頄堨溂氅�, crRNA 氚办棿鞚� 韱淀暣 雼れ 響滌爜 韼胳鞚� 臧�電ロ暔鞚� 頇曥澑頄堨姷雼堧嫟.
霕愴暅 GYS1 須唽臧� 瓿茧皽順勲悳 瓴冹潉 頇曥澑頃� 雮滌唽鞎� 靹疙彫欤茧ゼ 靹标车鞝侅溂搿� 韥措頇旐晿鞐� 鞎诫 鞀ろ伂毽嫕, 鞐瓣惮 韺岉姼雱堨嫮, 歆勲嫧 臧滊皽 霌� 歃夑皝鞝侅澑 靸侅梾鞝� 頇滌毄 臧�電レ劚鞚� 氤挫棳欤检棃鞀惦媹雼�. 鞚措姅 SOHM鞚� 鞝勲灥鞝� 韺岉姼雱堨嫮 氚� 霛检澊靹犾姢 旮绊殞鞚� 鞙犽Μ頃� 鞙勳箻鞐� 霊愲┌, 鞙犾爠觳� 韼胳 鞁滌灔鞚� 鞐绊弶攴� 靹膘灔毳� 16.1%搿� 2030雲勱箤歆� $25 billion by 2030 攴滊鞐� 鞚措ゼ 瓴冹溂搿� 鞝勲霅╇媹雼�.
SOHM (OTC:SHMN) a r茅alis茅 une avanc茅e importante dans la technologie d'茅dition g茅nomique avec sa plateforme propri茅taire ABBIE version 2. L'entreprise a d茅montr茅 avec succ猫s que son domaine dCas12a avanc茅 peut modifier efficacement des cellules humaines, permettant des 茅ditions multi-cibles via des matrices de crRNA.
Elle a 茅galement clon茅 avec succ猫s une lign茅e cellulaire de cancer de l'ovaire pr茅sentant une surexpression confirm茅e de l'enzyme GYS1, montrant des applications commerciales imm茅diates en criblage de m茅dicaments, partenariats de recherche et d茅veloppement de diagnostics. Cela positionne SOHM pour des partenariats strat茅giques et des opportunit茅s de licence sur le march茅 de l'茅dition g茅nomique en forte croissance, estim茅 atteindre $25 billion by 2030 avec un TCAC de 16,1%.
SOHM (OTC:SHMN) hat mit seiner firmeneigenen ABBIE Plattform Version 2 einen bedeutenden Durchbruch in der Geneditierungstechnologie erzielt. Das Unternehmen hat erfolgreich nachgewiesen, dass seine fortschrittliche dCas12a-Dom盲ne menschliche Zellen effektiv modifizieren kann und Mehrfachzielbearbeitungen mittels crRNA-Arrays erm枚glicht.
Ferner clonierte das Unternehmen erfolgreich eine Ovarialkarzinom-Zelllinie mit nachgewiesener 脺berexpression des Enzyms GYS1, was unmittelbare kommerzielle Anwendungen in der Wirkstoffscreening, Forschungskooperationen und Diagnostikentwicklung demonstriert. Damit positioniert sich SOHM f眉r strategische Partnerschaften und Lizenzierungschancen in dem schnell wachsenden Geneditierungsmarkt, der voraussichtlich bis 2030 $25 billion by 2030 erreichen wird bei einer CAGR von 16,1%.
- Successfully demonstrated advanced dCas12a domain technology for human cell modification
- Achieved multi-target editing capabilities through crRNA arrays
- Successfully cloned ovarian cancer cell line with GYS1 enzyme overexpression
- Positioned to capture share of growing genome editing market projected to reach $25B by 2030
- Enhanced potential for strategic partnerships and licensing opportunities
- Early-stage development company with inherent uncertainties
- Operating in highly competitive gene editing market
- No immediate revenue generation from technology platform
Advanced dCas12a Technology Successfully Modifies Human Cells, Positioning Company for Multi-Target Editing Capabilities
CHINO HILLS, CALIFORNIA / / August 26, 2025 / SOHM, Inc. (OTC PINK:SHMN), - SOHM, a leading pharmaceutical company developing next-generation gene editing solutions, today announced a significant milestone in the development of its proprietary ABBIE platform. The company has successfully demonstrated that ABBIE version 2, featuring an advanced dCas12a domain, can effectively modify cultured human cells, marking a critical advancement toward commercial-ready gene editing technology.
Breakthrough Technology Platform
This latest achievement represents a substantial upgrade from previous iterations, with the new dCas12a domain replacing the earlier dCas9 technology to deliver enhanced functionality and precision. The breakthrough positions SOHM to pursue simultaneous multi-target editing capabilities through crRNA arrays, potentially offering unprecedented efficiency in gene modification applications.
"This milestone validates our scientific approach and brings us significantly closer to realizing the full potential of our ABBIE platform," said Dr. David Aguilar, COO.
Proven Applications in Drug Discovery
Complementing the core platform advancement, SOHM has successfully cloned an ovarian cancer cell line with confirmed GYS1 enzyme overexpression. These specialized cellular tools demonstrate immediate commercial applications including:
Drug screening capabilities for targeted therapeutics such as GYS1 inhibitors
Research applications for academic and pharmaceutical partnerships
Diagnostic development opportunities across multiple therapeutic areas
Strategic Partnership and Licensing Implications
The technological advancements significantly enhance and improve SOHM's position for strategic partnerships and out licensing opportunities. The proven ability to create specialized cellular tools and modify human cells positions the company to engage with pharmaceutical partners, research institutions, and biotechnology companies seeking advanced gene editing solutions.
The company's out licensing strategy will focus on leveraging the ABBIE platform's multi-target capabilities and proven cellular engineering applications to create value across multiple therapeutic areas and research applications.
Revenue Implications:
Global Gene Editing Market: The global genome editing market size was estimated at USD 9.78 billion in 2024 and is projected to reach USD 25.00 billion by 2030, growing at a CAGR of
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted solutions for gene editing. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: [email protected]
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc.
View the original on ACCESS Newswire
FAQ
What breakthrough did SOHM (SHMN) announce in gene editing technology?
How large is the genome editing market potential for SOHM (SHMN)?
What immediate commercial applications does SOHM's technology offer?
How does SOHM's new dCas12a technology differ from previous versions?
What strategic opportunities does this breakthrough create for SOHM?
